


# Accepted Manuscript



*Sost* haploinsufficiency provokes peracute lethal cardiac tamponade without rescuing the osteopenia in a mouse model of excess glucocorticoids

Behzad Javaheri, Eleanor Herbert, Mark Hopkinson, Ahmed Al-Jazzar, Andrew A. Pitsillides

PII: S0002-9440(18)30697-7

DOI: <https://doi.org/10.1016/j.ajpath.2018.12.007>

Reference: AJPA 3071

To appear in: *The American Journal of Pathology*

Received Date: 29 August 2018

Revised Date: 21 November 2018

Accepted Date: 7 December 2018

Please cite this article as: Javaheri B, Herbert E, Hopkinson M, Al-Jazzar A, Pitsillides AA, *Sost* haploinsufficiency provokes peracute lethal cardiac tamponade without rescuing the osteopenia in a mouse model of excess glucocorticoids, *The American Journal of Pathology* (2019), doi: <https://doi.org/10.1016/j.ajpath.2018.12.007>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

***Sost* haploinsufficiency provokes peracute lethal cardiac tamponade without rescuing the osteopenia in a mouse model of excess glucocorticoids**

Behzad Javaheri<sup>1</sup>, Eleanor Herbert<sup>1,2</sup>, Mark, Hopkinson<sup>1</sup>, Ahmed Al-Jazzar<sup>3</sup>, Andrew A Pitsillides<sup>1</sup>

<sup>1</sup>Department of Comparative Biomedical Sciences, The Royal Veterinary College, London, United Kingdom

<sup>2</sup>Experimental Histopathology, The Francis Crick Institute, London, United Kingdom

<sup>3</sup>College of Veterinary Medicine, King Faisal University, Al-Hofuf, Saudi Arabia

**Short Title:** Sclerostin and lethal cardiac tamponade.

**Funding:** Supported by funding from the BBSRC BB/I014608/1 and Arthritis Research UK 20581 (A.A.P).

**Corresponding Author:** Behzad Javaheri Ph.D., Department of Comparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 0TU, United Kingdom. Email: [bjavaheri@rvc.ac.uk](mailto:bjavaheri@rvc.ac.uk)

**Disclosures:** None declared.

**Abstract**

Glucocorticoid-induced secondary osteoporosis is the most predictable side-effect of this anti-inflammatory. One of the main mechanisms by which glucocorticoids achieve such deleterious outcome in bone is by antagonizing Wnt/ $\beta$ -catenin signalling. Sclerostin, encoded by *Sost* gene, is the main negative regulator of the pro-formative and anti-resorptive role of the Wnt signaling pathway in the skeleton. We hypothesized that the partial inactivation of sclerostin function by genetic manipulation will rescue the osteopenia induced by high endogenous glucocorticoid levels. *Sost*-deficient mice were crossed with an established mouse model of excess glucocorticoids and the effects on bone mass and structure were evaluated. *Sost* haploinsufficiency did not rescue the low bone mass induced by high glucocorticoids. Intriguingly, the critical manifestation of *Sost*-deficiency combined with glucocorticoid excess was sporadic, sudden, unprovoked, and non-convulsive death. Detailed histopathological analysis in a wide range of tissues identified peracute haemopericardium and cardiac tamponade to be the cause. These preclinical studies reveal outcomes with direct relevance to ongoing clinical trials exploring the use of anti-sclerostin antibodies as a treatment for osteoporosis. They particularly highlight a potential for increased cardiovascular risk and may inform improved stratification of patients that might otherwise benefit from anti-sclerostin antibody treatment.

## Introduction

Glucocorticoids (GCs) are anti-inflammatory molecules synthesized and secreted by the adrenal glands that exert significant influence on the physiological functioning of several systems including adaptation to stress, metabolism, and regulation of immune responses. The signalling axis of GC consists of the hypothalamic-pituitary-adrenal axis influenced by many factors including neuroinflammation, physical stress, circadian rhythm, and negative feedback. GCs are used in the treatment of various diseases, such as asthma, rheumatoid arthritis, and systemic lupus erythematosus<sup>1-4</sup> with many reported side effects<sup>5, 6</sup>. Significantly, GC-induced osteoporosis (GIO) is the most predictable side effect and the commonest cause of secondary osteoporosis leading to increased fracture risk in 30% to 50% of patients receiving GCs<sup>5-9</sup>. Thus, there remains a significant unmet clinical need for the development of therapies to prevent and/or treat GIO.

The central feature in the pathogenesis of GIO is the suppression of bone formation. Previous studies suggest that GCs decrease the number and function of osteoblasts via a reduction in osteoblastogenesis and impairment in osteoblastic differentiation and maturation<sup>10, 11</sup>. This consequently favors adipogenesis, most likely dictated by up-regulation of peroxisome proliferator-activated receptor  $\gamma$  2 (PPAR $\gamma$ 2), leading to increased bone marrow adiposity<sup>12-15</sup>. In addition, GCs decrease osteoblast viability and activity, ultimately leading to a reduction in bone mass and compromised bone structure<sup>11</sup>. Osteocytes are the other key players in GIO since GCs induce their apoptosis<sup>16-18</sup>. This is likely achieved via the GC-mediated disruption of the osteocyte-lacunar-canalicular network, essential for osteocyte viability and maintenance of the bone's material properties<sup>11</sup>. These changes may explain the impairment of the biomechanical properties in the surrounding bone<sup>16</sup> and account for the loss of bone strength that occurs before the loss of BMD<sup>19</sup>.

One of the mechanisms by which GCs drive bone loss is via inhibition of the Wnt/ $\beta$ -catenin signalling pathway<sup>15, 20-22</sup>, critical for the differentiation of mesenchymal cells toward mature osteoblasts, bone formation, and mechanoadaptive responses<sup>11, 16, 23, 24</sup>. A natural antagonist of Wnt signalling, sclerostin (*Sost* gene product), predominantly secreted by osteocytes is a potent inhibitor of osteoblastic mineralization<sup>25-27</sup>. Thus its deficiency provokes marked increases in bone mass achieved via a range of targets<sup>28-39</sup>, without any significant impact on osteocyte differentiation<sup>40, 41</sup>.

Several studies have reported contradictory results on the relationship between GC excess and sclerostin<sup>42-46</sup>. Previous studies have reported that *in vivo* anti-sclerostin antibody treatment prevents the reduction in bone mass and strength induced by GC excess<sup>42, 43</sup>. Despite these established links between sclerostin levels and the prevention of GC-induced changes in bone mass, there remains controversy regarding how these links impact human patients, in which there have been discordant reports of decreased serum sclerostin in patients following one week of GC treatment, and increased serum sclerostin at later time points<sup>44</sup>. Similar disparities in the levels of sclerostin are also seen in GC-related disease states, where both increased and decreased levels are reported in patients with excess GC<sup>45, 46</sup>. The reasons for these contradictory observations on the relationship between sclerostin and excess glucocorticoids are unclear, raising the question whether modulation of sclerostin function indeed counteracts the deleterious effect of endogenously-raised GC levels on bone mass and strength.

We tested this possibility by determining whether genetically-determined sclerostin deficiency was capable of rescuing the compromised bone mass that occurs with GC excess. To address this question, sclerostin-deficient mice were crossed with an established mouse

model of GC excess due to an N-ethyl-N-nitrosourea-induced mutation in corticotropin-releasing hormone (*Crh*)<sup>47</sup> and the effects on bone mass and structure were evaluated along with detailed histopathological analysis in a wide range of tissues. Our preclinical findings are relevant to ongoing clinical trials in which serious fatal cardiovascular adverse events were reported in patients receiving anti-sclerostin antibody. They particularly highlight a potential need for patient stratification to help realize the potential benefit of such treatment.

## Materials and Methods

### Animals

Frozen sperm from a male *Sost* knockout (KO) mouse in the C57BL/6NTac background was purchased from the Knockout Mouse Project Repository at the University of California Davis, CA, and used to fertilize ova from C57BL/6J wild-type (WT) mice as described previously<sup>40</sup>; hetero/haplozygosity was confirmed by genotyping. The mouse model for excessive circulating GC concentrations was a gift from Medical Research Council (Oxfordshire, UK) and was generated in C57BL/6J mice by an N-ethyl-N-nitrosourea-induced mutation in corticotropin-releasing hormone (*Crh*) at -120 bp of the promoter region resulting in a gain-of-function mutation (*Crh*<sup>+/-120</sup>) and mated with C3H/HeH as described previously<sup>47</sup>. Female *Sost* homozygous KO (*Sost*<sup>-/-</sup>) mice were crossed with male *Crh*<sup>+/-120</sup> to produce *Sost-Crh*<sup>+/-120</sup> (*Sost* heterozygous/*Crh* heterozygous) and *Sost*<sup>+/-</sup> mice. Mice were housed in polypropylene cages under 12 h light/dark cycle at 21 ± 2°C with free access to Rat/Mouse One maintenance diet (Special Diet Services, Witham UK) and water ad libitum. The studies used only male mice throughout. All procedures complied with UK Animals (Scientific Procedures) Act 1986, were approved by the Royal Veterinary College's Ethics committee, and followed ARRIVE guidelines<sup>48</sup>.

### X-ray microcomputed tomography ( $\mu$ CT)

*In vivo* scanning of the entire right tibia at one month of age under 2% isoflurane-induced anesthesia and post-mortem at 2 months of age were achieved using a Skyscan 1176 X-ray microcomputed tomography machine (Skyscan, Kontich, Belgium). The X-ray tube was operated at 40kV, 600 $\mu$ A, with a voxel size of 9 $\mu$ m, an exposure of 2000ms and a rotation step of 0.800 degrees. The radiation dose from the  $\mu$ CT scanning was estimated to be approximately 500 mGy for each scan, which has been proved to cause no significant effect on bone adaptations<sup>49</sup>. Slices were reconstructed using NRecon1.6; trabecular and whole bone analysis was performed as described previously<sup>24</sup>. For morphometric trabecular analysis appearance of the trabecular ‘bridge’ connecting the two primary spongiosa bone ‘islands’ was set as a reference point for analysis of proximal tibia metaphyseal trabecular bone; 5% of the total bone length from this point (towards diaphysis) was used. For cortical analysis; following segmentation, alignment and removal of fibula, a minimum threshold was used in “Slice Geometry” to calculate mass: cross-sectional area (CSA), mean cross-sectional thickness (Cs.Th), second moment of area around minor axis ( $I_{\min}$ ), second moment of area around major axis ( $I_{\max}$ ), and predicted resistance to torsion (J) along a central 70% portion of the entire tibia length excluding regions that contained trabecular bone.

### Histological analysis

Tibia, heart, lungs, liver, spleen, kidneys, and brain were fixed in 4% formaldehyde (from paraformaldehyde Alfa Aesar Inc., Ward Hill, MA) and stored in 70% EtOH prior to routine processing into paraffin and production of slides sectioned at 4 $\mu$ m and stained with hematoxylin and eosin. Stained slides were evaluated by a board-certified Veterinary Pathologist (EH at The Francis Crick Institute, London, UK)<sup>50</sup>. Total numbers of animals examined were: *Sost*<sup>+/+</sup> WT (n = 4), *Sost*<sup>+/-</sup> heterozygous KO (n = 7), *Sost*<sup>-/-</sup> homozygous KO

(n = 4), *Crh*<sup>+/+</sup> WT (n = 4), *Crh*<sup>+/-120</sup> heterozygous KO (n = 4), and *Sost-Crh*<sup>+/-120</sup> heterozygous (n = 5). In addition, *Sost-Crh*<sup>+/-120</sup> (n=3) which spontaneously died were stored in 70% EtOH and examined histologically. Hearts from these animals were examined using multiple step levels and extensive sectioning throughout the block.

#### Statistical analyses

These were performed using “R”, version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria; <http://www.r-project.org>; last accessed August 29, 2018). Measurements were summarized as means ± SEM. Linear model (two-way analysis of variance) was used to determine the effects of age (one and two months) and genotype (*Sost* heterozygous and homozygous as well as *Crh* heterozygous and double *Sost-Crh* heterozygous and their corresponding WT littermates) and their interaction on all phenotypic measurements. Bonferroni post-hoc correction was performed for whole bone measurements. The statistical significance level was set at 5%.

## Results

### ***Sost* haploinsufficiency does not rescue compromised bone mass induced by excessive GC**

The designed studies tested whether genetically-determined *Sost* deficiency rescues low bone mass induced by excessive GC *in vivo*. Trabecular bone was analyzed and the entire tibial cortex was analyzed proximodistally in a non-biased fashion at 1 and 2 months of age. Both age and genotype independently affected the cortical cross-sectional area (CSA) and significant interaction was evident between age and genotype along the entire tibial length (Fig. 1A-B). The detailed post-hoc analyses at one month of age revealed, as expected, significantly higher CSA in *Sost* homozygous KO (*Sost*<sup>-/-</sup>) compared to *Sost*<sup>+/+</sup>WT mice (Fig.

1A-B) as well  $Sost^{-/-}$  compared with  $Sost^{+/-}$  along the entire tibia; unexpectedly lower cortical CSA was observed in restricted regions of the tibia in  $Sost^{+/-}$  compared with  $Sost^{+/+}$ WT littermates (Fig. 1A-B). At two months of age, CSA was significantly higher in  $Sost^{+/-}$  compared with  $Sost^{+/+}$ WT between 15% to 85% of the length and also in  $Sost^{-/-}$  compared with  $Sost^{+/+}$ WT and  $Sost^{+/-}$  across the entire tibial cortex.

Analysis of mice with excessive endogenous GCs at one month of age failed to find any significant differences in cortical CSA at any location along the tibia in WT  $Crh$  ( $Crh^{+/+}$ WT), heterozygous  $Crh$  ( $Crh^{+/-120}$ ), or mice heterozygous for both  $Crh$  and  $Sost$  ( $Sost-Crh^{+/-120}$ ) (Fig. 1A-B). In contrast, in mice aged two months, CSA was, as expected, significantly lower in  $Crh^{+/-120}$  compared with  $Crh^{+/+}$ WT and also lower in  $Sost-Crh^{+/-120}$  compared with  $Crh^{+/+}$  between ~25% to 85% of the tibial length. Intriguingly, no significant rescue in the reduction of CSA was observed at any location in tibia from  $Sost-Crh^{+/-120}$  mice compared with  $Crh^{+/-120}$ . Evaluation of J, a measure of predicted resistance to torsion, showed identical trends indicating that  $Sost$  haploinsufficiency also fails to rescue GC-induced decreases in the tibia's architectural strength (Supplemental Figure S1A-B). Further interrogation of cortical bone revealed that mean cortical cross-sectional thickness (Supplemental Figure S2), second area around minor axis (Supplemental Figure S3), and around major axis (Supplemental Figure S4) also indicate that  $Sost$  haploinsufficiency failed to rescue  $Crh^{+/-120}$  induced compromise in cortical bone mass and architecture. Our evaluation of age-related changes in the WT mice of both  $Sost^{-/-}$  (C57BL/6NTac/ C57BL/6J) and  $Crh^{+/-120}$  (C57BL/6J/ C3H/HeH) backgrounds revealed greater growth kinetics within the latter, between one and two months of age, suggesting that there is ample scope for any effects of the combined genetic manipulation to be realized (Supplemental Figure S5).

In addition to microCT analysis of cortical bone, tibial trabecular bone were analyzed. Percent bone volume (BV/TV) was significantly greater in mice lacking both copies of *Sost* (*Sost*<sup>-/-</sup>), while a trend which did not reach levels of statistical significance was observed for enhanced BV/TV in mice lacking a single copy (*Sost*<sup>+/-</sup>, Fig. 2A). This elevation of BV/TV in *Sost*<sup>-/-</sup> mice was linked with enhanced bone volume (BV), trabecular number (Tb.N), and thickness (Tb.Th), and lower trabecular separation; neither of these parameters alone reached statistical significance (Fig. 2A). The analysis also showed a trend for lower trabecular BV/TV in mice with excess glucocorticoids (*Crh*<sup>+/-120</sup>) and no significant modification of BV/TV in *Sost-Crh*<sup>+/-120</sup> mice (Fig. 2A). In agreement with the microCT data, detailed histological evaluation of tibia structure revealed thicker cortices in tibiae from mice lacking either one (*Sost*<sup>+/-</sup>) or both copies (*Sost*<sup>-/-</sup>) of functional *Sost* compared with tibia from *Sost*<sup>+/+</sup>WT mice (Fig. 2B-G). Thinner cortices were also observed in *Crh*<sup>+/-120</sup> mutant mice compared with tibiae from their *Crh*<sup>+/+</sup>WT littermates. In agreement with 3D quantification, tibiae from mice harboring both *Sost*<sup>+/-</sup> and *Crh*<sup>+/-120</sup> (*Sost-Crh*<sup>+/-120</sup>) were similar to *Crh*<sup>+/-120</sup>, indicating a failure of *Sost*<sup>+/-</sup> to rescue the effects of GC excess on bone mass (Fig. 2E-G). Together, the detailed comparison of bone by both histology and microCT revealed at two months of age that: i) both hetero- and homozygous *Sost*-deficient mice exhibit significantly greater bone mass and predicted strength; ii) heterozygous *Crh* mutation leads to a compromised bone mass and strength and, iii) *Sost* haploinsufficiency fails to rescue the compromised bone mass produced by excess GCs.

### **Combined *Sost* haploinsufficiency and *Crh*<sup>+/-120</sup> related GC excess provoke peracute lethal cardiac tamponade**

In the studies examining potential rescue of excess GC-related low bone mass by deletion of a single *Sost* allele, sudden, unprovoked, non-convulsive death of ~10% of total *Sost-Crh*<sup>+/-</sup>

offspring was observed between one to two month of age. No such incidences occurred in either *Crh*<sup>+/-120</sup>, *Sost*<sup>-/-</sup> or their respective WT littermates. To identify the cause of this sudden death, a comprehensive histopathological examination of multiple tissues from all mouse strains was performed using H&E staining, which was scored using a semi-quantitative grading system. Examination of the brain, kidney, liver, lung, and spleen showed no signs of overt pathology in *Sost*<sup>+/+WT</sup>, *Sost*<sup>+/-</sup>, *Sost*<sup>-/-</sup>, *Crh*<sup>+/+WT</sup> or *Crh*<sup>+/-120</sup>, or *Sost-Crh*<sup>+/-120</sup> mice in which a propensity for sudden death was observed.

Intriguingly, evaluation of heart tissue in *Sost-Crh*<sup>+/-120</sup> mice with sudden death revealed all to have hemopericardium with a markedly expanded pericardial space containing a large number of densely packed, homogenously distributed erythrocytes and compression of the right ventricular (Fig. 3A) and right atrial lumen (Fig. 3B) in all mice which suffered from sudden death. Therefore, the cause of sudden death in these animals is considered to be due to peracute haemopericardium leading to cardiac tamponade. Hearts were examined at multiple step levels through the tissue to try to ascertain the origin of the hemorrhage; however, none could be identified. No significant findings were observed in the hearts of the remainder of the *Sost-Crh*<sup>+/-120</sup> mice, or in any of the *Sost*<sup>+/+WT</sup>, *Sost*<sup>+/-</sup>, *Sost*<sup>-/-</sup>, *Crh*<sup>+/+WT</sup>, and *Crh*<sup>+/-120</sup> mice.

## Discussion

Osteopenia due to excess GC mainly involves a decrease in bone formation, secondary to the effects on the activity and viability of osteoblasts and osteocytes, which ultimately leads to an impairment in bone strength. One of the main mechanisms by which GCs achieve such deleterious outcome in bone is by antagonizing Wnt/ $\beta$ -catenin signalling. Sclerostin, the product of the *Sost* gene, is the main negative regulator of the Wnt pathway in the skeleton.

Thus, sclerostin normally acts to suppress the pro-formative and anti-resorptive role of the Wnt signaling pathway. Herein, the hypothesis that the partial inactivation of sclerostin function by genetic manipulation will be capable of rescuing the low bone mass induced by high endogenous GC levels was tested.

In contrast, it was found instead that *Sost* haploinsufficiency was not capable of rescuing the low bone mass induced by high GC. These findings do not agree with previous studies which reported that transient anti-sclerostin antibody treatment rescued GC-induced low bone mass<sup>42, 43</sup>. It is possible that these dissimilar observations arise due solely to differences in experimental design and analysis. These studies undertook a non-biased analysis of almost the entire tibial cortex adjusting for GC-induced divergence in bone length and thus ensure comparisons are made at precisely-matched anatomical locations and volumes. Although Marenzana et al reported small, significant protective effects of anti-sclerostin antibody treatment against an exogenous GC-induced reduction in cortical bone volume at the femur mid-shaft, they did not find similar rescue of GC-induced reduction in bone length. The methods employed, however, made no apparent correction for this growth retardation, and thus measurement of equivalent bone volumes was not ensured<sup>43</sup>. An alternative explanation is that our studies encompass the developmental effect of excessive GC and *Sost* haploinsufficiency and it remains possible that this may diverge from the outcome of transient anti-sclerostin antibody treatment of adult mice which have induced GC excess<sup>42, 43</sup>.

Sclerostin has long been considered an effective target for treating osteoporosis. The most recent phase III clinical trial of romosozumab (an anti-sclerostin antibody), to our knowledge, was however hampered by unforeseen, increased adverse cardiovascular risk<sup>51</sup> resulting in refusal to approve this treatment by the Food and Drug Administration. The finding that a

combination of high endogenous GC levels together with *Sost* haploinsufficiency results in sudden death with histopathological, marked haemopericardium, is therefore intriguing. The pericardial space in these mice was found to be markedly enlarged by densely packed erythrocytes with compression of the heart lumen, consistent with sudden death from cardiac tamponade.

To the authors' knowledge, cardiac tamponade secondary to spontaneous haemopericardium has not been reported before in mice. In other species, causes of spontaneous haemopericardium, occur due to rupture of the intra-pericardial portion of the aorta or pulmonary artery, rupture of a coronary vessel, cardiac rupture after an acute myocardial infarct or rupture of an atrium secondary to atrial thrombosis, blood dyscrasias, and neoplasia. The histological examinations, however, did not localize the site of rupture/hemorrhage or reveal an overt underlying pathology. Microscopic examination of the heart and major blood vessels in both affected and unaffected animals also failed to disclose any possible predisposing lesions such as aneurysm, congenital blood vessel anomaly, or cardiac disease.

There are several possible explanations that may clarify the underpinning mechanisms whereby sclerostin exerts a regulatory role in the cardiovascular system. Although sclerostin is reported to be expressed in the aorta<sup>52-54</sup>, neither *Sost* KO mice in this study or others nor human patients with sclerosteosis or van Buchem's disease due to mutations in the *SOST* gene, exhibit any greater risk of cardiovascular complications<sup>55-58</sup>. Furthermore, a case study by van Lierop et al reported that glucocorticoid treatment does not lead to adverse cardiovascular effects in a van Buchem high bone mass patient with mutation in the *SOST* gene<sup>59</sup>. In addition, Sato et al reported that *Sost* homozygous KO mice treated with

glucocorticoids maintain structural and material mechanical properties despite increased osteocyte apoptosis and that no cardiovascular complications were reported<sup>60</sup>. It is possible that differences in our findings to those reported by aforementioned studies can be explained by the fact that the excess glucocorticoids present in *Crh*<sup>+/-120</sup> mice during developmental and later life-course may affect multiple organs including the cardiovascular system.

Other studies have also reported up-regulation of sclerostin in foci of vascular and valvular calcification<sup>61-64</sup>. Our detailed histopathological examinations were not able to find any signs of calcification in any mice in this study. This agrees with other animal studies showing that sclerostin is unlikely to be involved in vascular mineralization<sup>53, 65</sup>. There is no evidence to suggest that sclerostin plays a causal role in cardiovascular disease, rather recent studies have reported an association between sclerostin levels and cardiovascular disorders<sup>66-69</sup>. The precise function of sclerostin in the regulation of the cardiovascular system remains to be defined.

A limitation in our studies is the lack of any measured levels of circulatory sclerostin and thus it remains to be verified that the *Sost* genetic haploinsufficiency in our studies is necessarily reflected in a change in expression levels. The ‘middle level’ bone phenotype observed in the *Sost* haploinsufficient mice (either in mice with or without the *Crh*<sup>+/-120</sup> mutation) in which true heterozygosity was also confirmed by genotyping makes it highly likely that sclerostin levels are modified accordingly. The levels might be lower in the *Sost-Crh*<sup>+/-120</sup> mice than in *Crh*<sup>+/-120</sup> mice. Another limitation is that whether anti-sclerostin antibody-mediated blockade of sclerostin function is equivalent to genetic insufficiency cannot be predicted.

Nonetheless, the critical manifestation of *Sost*-deficiency combined with GC excess in our study is sporadic, sudden, unprovoked, and non-convulsive death linked to peracute haemopericardium and cardiac tamponade. Tamponade has been linked to many conditions, including cancer, uremia, hypothyroidism, and pericarditis, where enlargement of pericardium arises gradually<sup>70-73</sup>. No evidence for such conditions was found in this study. The rapid haemopericardium-related tamponade observed is more consistent with myocardial rupture, but this was not found upon detailed pathological examination using multiple step levels sectioned throughout the heart. The cause of this tamponade and death in some *Sost-Crh1*<sup>+/-120</sup> remains unexplained; this is confounded by a lack of any abnormal preceding changes evident in their living equivalents; no predisposing lesions, such as aneurysm, focal thinning, or disruption of the myocardium or coronary vessels were observed histologically in the unaffected animals. It is tempting to speculate upon the likely mechanisms. Experiments that explore whether unrestricted Wnt signaling, due to *Sost*-deficiency, interacts with regulators of inflammatory processes, as seen in circumstances such as GC excess, may explain such serious adverse cardiovascular events. These findings using mouse pre-clinical models, therefore, prompt further studies aimed at deciphering their clinical significance and the underpinning molecular mechanisms by which GC-induced osteopenia might be better-targeted without risk of cardiovascular side-effects.

**Acknowledgements**

The *Crh* mouse model for excessive circulating GC concentrations was a gift from Medical Research Council (Oxfordshire, UK). We thank Professor Cheryl Scudamore for highlighting the availability of these *Crh* mice as a robust model of GC excess and Prof Chantal Chenu for her critical reading of the manuscript.

B.J., E.H., M.H., and A.A. collected data. B.J., E.H., and A.P. wrote the manuscript. All authors approved the manuscript.

## References

- [1] Buttgereit F, Burmester G-R, Lipworth BJ: Optimised glucocorticoid therapy: the sharpening of an old spear. *The Lancet* 2005, 365:801-3.
- [2] Ogoshi T, Hagino H, Fukata S, Tanishima S, Okano T, Teshima R: Influence of glucocorticoid on bone in 3-, 6-, and 12-month-old rats as determined by bone mass and histomorphometry. *Modern Rheumatology* 2008, 18:552-61.
- [3] McLaughlin F, Mackintosh J, Hayes B, McLaren A, Uings I, Salmon P, Humphreys J, Meldrum E, Farrow S: Glucocorticoid-induced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography, and biochemical markers. *Bone* 2002, 30:924-30.
- [4] Bultink IE, Baden M, Lems WF: Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. *Expert Opinion on Pharmacotherapy* 2013, 14:185-97.
- [5] Humphrey E, Williams JH, Davie MW, Marshall MJ: Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. *Bone* 2006, 38:652-61.
- [6] Schäcke H, Döcke W-D, Asadullah K: Mechanisms involved in the side effects of glucocorticoids. *Pharmacology & Therapeutics* 2002, 96:23-43.
- [7] Chen Z, Xue J, Shen T, Mu S, Fu Q: Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway. *International Journal of Molecular Medicine* 2016, 37:329-38.
- [8] Adachi JD, Bensen WG, Hodzman AB: Corticosteroid-induced osteoporosis. *Seminars in Arthritis and Rheumatism*: Elsevier, 1993. pp. 375-84.
- [9] Saag KG: Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. *The American Journal of Medicine* 1997, 103:S31-S9.
- [10] Canalis E: Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. *Nature Reviews Endocrinology* 2013, 9:575.
- [11] Canalis E, Mazziotti G, Giustina A, Bilezikian J: Glucocorticoid-induced osteoporosis: pathophysiology and therapy. *Osteoporosis International* 2007, 18:1319-28.
- [12] Hoepfner LH, Secreto FJ, Westendorf JJ: Wnt signaling as a therapeutic target for bone diseases. *Expert Opinion on Therapeutic Targets* 2009, 13:485-96.
- [13] Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE: Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. *Arthritis & Rheumatism* 2008, 58:1674-86.
- [14] Cavagnini F, Croci M, Putignano P, Petroni M, Invitti C: Glucocorticoids and neuroendocrine function. *International Journal of Obesity* 2000, 24:S77.

- [15] Georgiou KR, Hui SK, Xian CJ: Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy. *American Journal of Stem Cells* 2012, 1:205.
- [16] Compston J: Management of glucocorticoid-induced osteoporosis. *Nature Reviews Rheumatology* 2010, 6:82.
- [17] Bellido T: Antagonistic interplay between mechanical forces and glucocorticoids in bone: a tale of kinases. *Journal of Cellular Biochemistry* 2010, 111:1-6.
- [18] Plotkin LI, Manolagas SC, Bellido T: Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival evidence for inside-out signaling leading to anoikis. *Journal of Biological Chemistry* 2007, 282:24120-30.
- [19] Weinstein RS: Glucocorticoid-induced bone disease. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism* 2013:473-81.
- [20] Ohnaka K: Wnt signaling and glucocorticoid-induced osteoporosis. *Clinical Calcium* 2006, 16:1812-6.
- [21] Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, Lane NE: Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. *Arthritis & Rheumatism* 2008, 58:3485-97.
- [22] Gourlay M, Franceschini N, Sheyn Y: Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. *Clinical Rheumatology* 2007, 26:144-53.
- [23] Javaheri B, Stern AR, Lara N, Dallas M, Zhao H, Liu Y, Bonewald LF, Johnson ML: Deletion of a Single  $\beta$ -Catenin Allele in Osteocytes Abolishes the Bone Anabolic Response to Loading. *Journal of Bone and Mineral Research* 2014, 29:705-15.
- [24] Javaheri B, Carriero A, Wood M, De Souza R, Lee PD, Shefelbine S, Pitsillides AA: Transient peak-strain matching partially recovers the age-impaired mechanoadaptive cortical bone response. *Scientific reports* 2018, 8:6636.
- [25] Weivoda MM, Youssef SJ, Oursler MJ: Sclerostin expression and functions beyond the osteocyte. *Bone* 2017, 96:45-50.
- [26] Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W: A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. *Bone* 2005, 36:943-7.
- [27] Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L: Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/ $\beta$ -catenin signaling. *Journal of Bone and Mineral Research* 2009, 24:1651-61.
- [28] Reya T, Clevers H: Wnt signalling in stem cells and cancer. *Nature* 2005, 434:843-50.
- [29] Kato M, Patel MS, Lévassieur R, Lobov I, Chang BH, Glass DA, 2nd, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L: Cbfa1-independent decrease in

osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in *Lrp5*, a Wnt coreceptor. *J Cell Biol* 2002, 157:303-14.

[30] Kato M, Patel MS, Levasseur R, Lobov I, Chang BH-J, Glass DA, Hartmann C, Li L, Hwang T-H, Brayton CF: *Cbfa1*-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in *Lrp5*, a Wnt coreceptor. *The Journal of Cell Biology* 2002, 157:303-14.

[31] Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert A-J, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS: The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. *Molecular Endocrinology* 2004, 18:1222-37.

[32] Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B: High bone mass in mice expressing a mutant *LRP5* gene. *Journal of Bone and Mineral Research* 2003, 18:960-74.

[33] Glass DA, 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. *Developmental Cell* 2005, 8:751-64.

[34] Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO: Essential role of beta-catenin in postnatal bone acquisition. *The Journal of Biological Chemistry* 2005, 280:21162-8.

[35] Johnson ML, Harnish K, Nusse R, Van Hul W: *LRP5* and Wnt signaling: a union made for bone. *Journal of Bone and Mineral Research* 2004, 19:1749-57.

[36] Armstrong VJ, Muzylak M, Sunters A, Zaman G, Saxon LK, Price JS, Lanyon LE: Wnt/beta-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor alpha. *The Journal of Biological Chemistry* 2007, 282:20715-27.

[37] Bex F, Green P, Marzolf J, Babij P, Yaworsky P, Kharode Y: The human *LRP5* G171V mutation in mice alters the skeletal response to limb unloading but not to ovariectomy. *Journal of Bone and Mineral Research* 2003, 18:p. S60.

[38] Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, Cullen DM, Zhao W, Li C, Kharode Y, Sauter L, Babij P, Brown EL, Hill AA, Akhter MP, Johnson ML, Recker RR, Komm BS, Bex FJ: Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. *The Journal of Biological Chemistry* 2006, 281:31720-8.

[39] Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH: The Wnt co-receptor *LRP5* is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. *The Journal of Biological Chemistry* 2006, 281:23698-711.

[40] Mosey H, Núñez JA, Goring A, Clarkin CE, Staines KA, Lee PD, Pitsillides AA, Javaheri B: *Sost* Deficiency does not alter Bone's lacunar or Vascular Porosity in Mice. *Frontiers in Materials* 2017, 4:27.

- [41] Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foerzler D, Van Hul W: Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). *Human Molecular Genetics* 2001, 10:537-43.
- [42] Yao W, Dai W, Jiang L, Lay E-A, Zhong Z, Ritchie R, Li X, Ke H, Lane N: Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. *Osteoporosis International* 2016, 27:283-94.
- [43] Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson M: Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. *Arthritis & Rheumatism* 2011, 63:2385-95.
- [44] Gifre L, Ruiz-Gaspa S, Monegal A, Nomdedeu B, Filella X, Guanabens N, Peris P: Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. *Bone* 2013, 57:272-6.
- [45] Belaya Z, Rozhinskaya L, Melnichenko G, Solodovnikov A, Dragunova N, Iljin A, Dzeranova L, Dedov I: Serum extracellular secreted antagonists of the canonical Wnt/ $\beta$ -catenin signaling pathway in patients with Cushing's syndrome. *Osteoporosis International* 2013, 24:2191-9.
- [46] Van Lierop A, van der Eerden A, Hamdy N, Hermus A, den Heijer M, Papapoulos S: Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. *The Journal of Clinical Endocrinology & Metabolism* 2012, 97:E1953-E7.
- [47] Bentley L, Esapa CT, Nesbit MA, Head RA, Evans H, Lath D, Scudamore CL, Hough TA, Podrini C, Hannan FM: An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess. *Endocrinology* 2014, 155:908-22.
- [48] Kilkeny C, Browne WJ, Cuthill IC, Emerson M, Altman DG: Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *PLoS biology* 2010, 8:e1000412.
- [49] Laperre K, Depypere M, van Gastel N, Torrekens S, Moermans K, Bogaerts R, Maes F, Carmeliet G: Development of micro-CT protocols for in vivo follow-up of mouse bone architecture without major radiation side effects. *Bone* 2011, 49:613-22.
- [50] Scudamore CL: *A Practical Guide to the Histology of the Mouse*: John Wiley & Sons, 2014.
- [51] Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A: Romosozumab or alendronate for fracture prevention in women with osteoporosis. *New England Journal of Medicine* 2017, 377:1417-27.
- [52] Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M: Proteomic characterization of extracellular space components in the human aorta. *Molecular & Cellular Proteomics* 2010:mcp. M110. 001693.

- [53] Chouinard L, Felx M, Mellal N, Varela A, Mann P, Jolette J, Samadfam R, Smith SY, Locher K, Buntich S: Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. *Regulatory Toxicology and Pharmacology* 2016, 81:212-22.
- [54] Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo P, Fu Y-H: Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. *The American Journal of Human Genetics* 2001, 68:577-89.
- [55] Vanhoenacker FM, Balemans W, Tan GJ, Dikkers FG, De Schepper AM, Mathysen DG, Bernaerts A, Van Hul W: Van Buchem disease: lifetime evolution of radioclinical features. *Skeletal Radiology* 2003, 32:708-18.
- [56] Van Buchem FSP, Prick JJG, Jaspar H: *Hyperostosis corticalis generalisata familiaris (van Buchem's disease)*: Excerpta Medica, 1976.
- [57] Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J: Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. *Journal of Bone and Mineral Research* 2008, 23:860-9.
- [58] Hamersma H, Gardner J, Beighton P: The natural history of sclerosteosis. *Clinical Genetics* 2003, 63:192-7.
- [59] van Lierop AH, Hamdy NA, Papapoulos SE: Glucocorticoids are not always deleterious for bone. *Journal of Bone and Mineral Research* 2010, 25:2796-800.
- [60] Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, Plotkin LI, Bellido T: Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost/Sclerostin. *Journal of Bone and Mineral Research* 2016, 31:1791-802.
- [61] Zhu D, Mackenzie NCW, Millan JL, Farquharson C, MacRae VE: The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. *PLoS ONE* 2011, 6:e19595.
- [62] Rukov JL, Gravesen E, Mace ML, Hofman-Bang J, Vinther J, Andersen CB, Lewin E, Olgaard K: Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA sequencing. *American Journal of Physiology-Renal Physiology* 2016, 310:F477-F91.
- [63] Kramann R, Kunter U, Brandenburg VM, Leisten I, Ehling J, Klinkhammer BM, Knüchel R, Floege J, Schneider RK: Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease. *Journal of Bone and Mineral Research* 2013, 28:2523-34.
- [64] Brandenburg VM, Kramann R, Koos R, Krüger T, Schurgers L, Mühlenbruch G, Hübner S, Gladziwa U, Drechsler C, Ketteler M: Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. *BMC Nephrology* 2013, 14:219.
- [65] Ominsky MS, Boyd SK, Varela A, Jolette J, Felx M, Doyle N, Mellal N, Smith SY, Locher K, Buntich S: Romosozumab improves bone mass and strength while maintaining

bone quality in ovariectomized cynomolgus monkeys. *Journal of Bone and Mineral Research* 2017, 32:788-801.

[66] Novo-Rodríguez C, García-Fontana B, Luna-Del Castillo JDD, Andújar-Vera F, Ávila-Rubio V, García-Fontana C, Morales-Santana S, Rozas-Moreno P, Muñoz-Torres M: Circulating levels of sclerostin are associated with cardiovascular mortality. *PloS ONE* 2018, 13:e0199504.

[67] Gaudio A, Fiore V, Rapisarda R, Sidoti MH, Xourafa A, Catalano A, Tringali G, Zanolì L, Signorelli SS, Fiore CE: Sclerostin is a possible candidate marker of arterial stiffness: Results from a cohort study in Catania. *Molecular Medicine Reports* 2017, 15:3420-4.

[68] Krishna SM, Seto S-W, Jose RJ, Li J, Morton SK, Biroş E, Wang Y, Nsengiyumva V, Lindeman JH, Loots GG: Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2017, 37:553-66.

[69] Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore CE: The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus. *Diabetes and Vascular Disease Research* 2014, 11:48-52.

[70] Okamoto H, Shinkai T, Yamakido M, Saijo N: Cardiac tamponade caused by primary lung cancer and the management of pericardial effusion. *Cancer* 1993, 71:93-8.

[71] Baldwin JJ, Edwards JE: Uremic pericarditis as a cause of cardiac tamponade. *Circulation* 1976, 53:896-901.

[72] Manolis AS, Varriale P, Ostrowski RM: Hypothyroid cardiac tamponade. *Archives of Internal Medicine* 1987, 147:1167-9.

[73] Kabukcu M, Demircioglu F, Yanik E, Basarici I, Ersel F: Pericardial tamponade and large pericardial effusions: causal factors and efficacy of percutaneous catheter drainage in 50 patients. *Texas Heart Institute Journal* 2004, 31:398.

## Figure Legends

Figure 1. *Sost* haploinsufficiency does not rescue low bone cross-sectional area induced by excessive GCs. **A:** Average cortical cross-sectional area (CSA) of *Sost* WT (dark blue; *Sost*<sup>+/+</sup>), *Sost* heterozygous KO (light blue; *Sost*<sup>+/-</sup>), *Sost* homozygous KO (turquoise; *Sost*<sup>-/-</sup>), *Crh* WT (dark red; *Crh*<sup>+/+</sup>), *Crh* heterozygous (orange; *Crh*<sup>+/-120</sup>), and double *Sost-Crh* heterozygous (plum; *Sost-Crh*<sup>+/-120</sup>) at one and two months of age. **B:** Graphical heatmap representation of statistical significance of the effect of genotype, age, their interactions as well as post-hoc analysis along a 15% to 85% portion of the whole tibia length excluding proximal and distal metaphyseal bone. Line graphs represent means  $\pm$  SEM (shadow). Group sizes were n = 8. Red  $P < 0.001$ , yellow  $0.001 \leq P < 0.01$ , green  $0.01 \leq P < 0.05$ , and blue  $P \geq 0.05$ .

Figure 2. Trabecular bone phenotype of *Sost* WT (*Sost*<sup>+/+</sup>); *Sost* heterozygous KO (*Sost*<sup>+/-</sup>); *Sost* homozygous KO (*Sost*<sup>-/-</sup>); *Crh* WT (*Crh*<sup>+/+</sup>); *Crh* heterozygous (*Crh*<sup>+/-120</sup>), and double *Sost-Crh* heterozygous (*Sost-Crh*<sup>+/-120</sup>) at two months of age. *Ex vivo* high-resolution analyses of the proximal metaphyseal tibia to determine **A:** trabecular bone volume (BV), trabecular total volume (TV), percent bone volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp). **B-G:** Representative hematoxylin and eosin-stained sections of tibia at two months of age. **B:** *Sost* WT (*Sost*<sup>+/+</sup>). **C:** *Sost* heterozygous KO (*Sost*<sup>+/-</sup>). **D:** *Sost* homozygous KO (*Sost*<sup>-/-</sup>). **E:** *Crh* WT (*Crh*<sup>+/+</sup>). **F:** *Crh* heterozygous (*Crh*<sup>+/-120</sup>). **G:** Double *Sost-Crh* heterozygous (*Sost-Crh*<sup>+/-120</sup>) with corresponding higher magnification demonstrating the structural differences between groups. Box-plots represent means  $\pm$  SEM. Group sizes were n = 8. \*  $P < 0.05$ .

Figure 3. *Sost* haploinsufficiency together with excessive GCs leads to peracute lethal cardiac tamponade. Two representative cases are displayed. **A:** Markedly expanded pericardial space (dashed line in center panel) with a large number of densely packed, homogenously distributed erythrocytes and compressed right ventricular lumen. **B:** Haemopericardium (dashed line in center panel) containing erythrocytes and a compressed right atrial lumen.

